Home » Crucell, DSM Biologics Announce PER.C6 Agreement With MorphoSys
Crucell, DSM Biologics Announce PER.C6 Agreement With MorphoSys
Dutch biotechnology company Crucell N.V. and DSM Biologics, a business unit of DSM Pharmaceutical Products, announced that German-based MorphoSys AG has decided to extend the PER.C6 technology licensing agreement entered in September 2004, exercising an option for clinical and commercial production of antibodies.
The Earth Times
The Earth Times
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May